<DOC>
	<DOCNO>NCT00787774</DOCNO>
	<brief_summary>Prospective study evaluate potential persistent viral effect raltegravir 20 treatment experience HIV patient incomplete viral suppression</brief_summary>
	<brief_title>Integrase Resistance Analysis HIV Patients Who Interrupted Raltegravir Due Incomplete Viral Suppression</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Subjects Raltegravircontaining regimen confirm virological failure ( VL &gt; 500c/mL &gt; 3 month ) . Patients treat raltegravircontaining regimen least 24 week . CD4 cell count &gt; 50 cell/mm3 . Adherence &gt; 90 % , measure short self report questionnaire 3 month precede study entry . No reasonable additional therapeutic option History suspicion alcohol drug use investigator 's opinion would likely compromise subject ' safety and/or study procedure . A positive urine drug test amphetamine , cocaine opioids two consecutive screening ( positive drug test study screen repeat baseline ) . Life expectancy le 6 month . Subject currently active AIDS defining illness ( Category C condition accord CDC Classification System HIV Infection 1993 ) follow 2 exception : 1 . Stable cutaneous Kaposi 's Sarcoma unlikely require form systemic therapy study period . 2 . Wasting syndrome due HIV infection , investigator 's opinion , actively progressive . Any active clinically significant disease ( e.g . TB , cardiac dysfunction ) finding screen medical history physical examination investigator 's opinion , would compromise outcome study . Pregnant breastfeed female . Renal impairment : serum creatinine &gt; 2 x ULN . Chronic Hepatitis B C ALT AST &gt; 3 x ULN . Acute Hepatitis A , B C. Acute Hepatitis A , B C. Any grade 3 4 toxicity accord enhance ACTG grade severity list , except grade 3 4 asymptomatic triglyceride/cholesterol elevation , isolate grade 3 increase GGT , grade 3 increase glucose , asymptomatic grade 3 increase amylase elevation lipase . Currently significant diarrhea , gastric stasis constipation investigator 's opinion could influence drug absorption bioavailability . Subjects clinical laboratory evidence significantly decrease hepatic function decompensation , irrespective liver enzyme level ( INR &gt; 1.3 albumin &lt; 30g/l bilirubin &gt; 2.5 x ULN ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>HIV</keyword>
	<keyword>resistance</keyword>
	<keyword>integrase</keyword>
</DOC>